« Return to News | Study Conduct

Greenphire chosen for long-term global trial

Wednesday, November 7, 2012 09:17 AM

King of Prussia, Penn.-based Greenphire, a provider of payment technologies for the clinical trials industry, said its ClinCard Technology Platform has been chosen for use in a large, phase III clinical trial to include more than 1,000 patients across six countries. The trial is expected to last more than five years. 

The ClinCard system will allow the sponsor to execute quick payments to patients globally in four different currencies, and will reduce the administrative burden on sites by replacing traditional manual processes with automated electronic payments. Greenphire said in previous studies, ClinCard decreased time spent on administrative tasks related to patient payments by up to 90% and reduced associated costs by up to 60%.

“By combining real-time patient payments in local currencies with automated patient messaging systems, the ClinCard system has been shown to increase patient retention by up to 11.7%, a particularly important consideration in a long-term study such as this,” said Sam Whitaker, Greenphire’s CEO and co-founder.  

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.